Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke

18. december 2015 opdateret af: Acorda Therapeutics
This is a multi-center, safety and tolerability study in subjects with chronic stable sensorimotor deficits after ischemic stroke. It has been designed as a double-blind, placebo-controlled, 2-period crossover study.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

83

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Forenede Stater
    • Alabama
      • Birmingham, Alabama, Forenede Stater, 35294
        • Acorda Site #011
    • California
      • La Jolla, California, Forenede Stater, 92103
        • Acorda Site #018
      • Newport Beach, California, Forenede Stater, 92663
        • Acorda Site #016
    • Connecticut
      • Fairfield, Connecticut, Forenede Stater, 06824
        • Acorda Site #006
    • Florida
      • Atlantis, Florida, Forenede Stater, 33462
        • Acorda Site #002
      • Fort Lauderdale, Florida, Forenede Stater, 33308
        • Acorda Site #015
    • Georgia
      • Decatur, Georgia, Forenede Stater, 30033
        • Acorda Site #003
    • Kentucky
      • Lexington, Kentucky, Forenede Stater, 40513
        • Acorda Site #021
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02118
        • Acorda Site #009
    • Michigan
      • Saginaw, Michigan, Forenede Stater, 48604
        • Acorda Site #017
    • Montana
      • Great Falls, Montana, Forenede Stater, 59405
        • Acorda Site #020
    • Nevada
      • Reno, Nevada, Forenede Stater, 89502
        • Acorda Site #023
    • New Jersey
      • New Brunswick, New Jersey, Forenede Stater, 08901
        • Acorda Site #022
    • New York
      • Buffalo, New York, Forenede Stater, 14220
        • Acorda Site #019
      • West Haverstraw, New York, Forenede Stater, 10993
        • Acorda Site #007
      • White Plains, New York, Forenede Stater, 10605
        • Acorda Site #004
    • North Carolina
      • Charlotte, North Carolina, Forenede Stater, 28207
        • Acorda Site #013
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forenede Stater, 19104
        • Acorda Site #001
    • Virginia
      • Norfolk, Virginia, Forenede Stater, 23507
        • Acorda Site #008
    • Washington
      • Bellevue, Washington, Forenede Stater, 98004
        • Acorda Site #010

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 85 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • History of a stable sensorimotor deficit due to an ischemic stroke, as confirmed by the Investigator with supportive prior imaging findings (MRI/ CT scan)
  • ≥ 6 months post-stroke
  • Have a body mass index (BMI) ranging between 18.0 - 35.0 kg/m,2 inclusive
  • Stable concomitant medication therapy regimen within 4 weeks of screening visit

Exclusion Criteria:

  • History of seizures, except simple febrile seizures
  • Moderate or severe renal impairment as defined by a calculated creatinine clearance of ≤ 50 mL/minute using the Cockcroft-Gault Equation
  • Botulinum toxin use within 2 months prior to the Screening Visit
  • Orthopedic surgical procedures in any of the extremities within the past 6 months
  • Diagnosis of multiple sclerosis

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Crossover opgave
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Placebo komparator: placebo/dalfampridine-ER

Subjects will be randomized at day 1 to one of two blinded treatment sequences (A or B) in a 2:1 ratio respectively, according to a randomization created prior to the start of the study:

Period 1 = days 1, 8 and 15. Period 2 = Days 22, 29, and 36
Medicin: placebo/dalfampridine-ER
Sequence A: placebo in Period 1 and dalfampridine-ER in Period 2. 10mg tablets, will be taken orally, twice daily approximately 12 hours apart
Placebo komparator: dalfampridine-ER/placebo

Subjects will be randomized at day 1 to one of two blinded treatment sequences (A or B) in a 2:1 ratio respectively, according to a randomization created prior to the start of the study:

Period 1 = days 1, 8 and 15. Period 2 = Days 22, 29, and 36
Medicin: dalfampridine-ER/placebo
Sequence B: dalfampridine-ER in Period 1 and placebo in Period 2. 10mg tablets, will be taken orally, twice daily approximately 12 hours apart

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Safety and Tolerability of Dalfampridine-ER in Subjects With Chronic Deficits After Ischemic Stroke Assessed by Number of Treatment Emergent Adverse Events (TEAEs)
Tidsramme: up to 36 days

A TEAE is defined as any adverse event with date of onset (or worsening) on or after the start-date of double-blind treatment through 7 days after the last dose of double-blind treatment.

The severity categories of mild, moderate or severe, are defined below:

  • Mild is defined as causing no limitation of usual activities
  • Moderate is defined as causing some limitation of usual activities
  • Severe is defined as causing inability to carry out usual activities
up to 36 days

Andre resultatmål

Resultatmål
Tidsramme
Walking Speed Measured by the Timed 25 Foot Walk Test (T25FW)
Tidsramme: Screening visit, Days 1, 8, 15, 22, 29 and 36
Screening visit, Days 1, 8, 15, 22, 29 and 36
Motor and Sensory Function as Measured by the Fugl-Meyer Assessment (FMA)
Tidsramme: Screening visit, Days 1, 8, 15, 22, 29, and 36
Screening visit, Days 1, 8, 15, 22, 29, and 36
Manual Dexterity as Measured by the Box and Block Test
Tidsramme: Days 1, 8, 15, 22, 29, and 36
Days 1, 8, 15, 22, 29, and 36
Assistance Required to Perform Activities of Daily Living (ADL) by the Functional Independence Measure (FIM) Scale
Tidsramme: Days 1, 8, 15, 22, 29, and 36
Days 1, 8, 15, 22, 29, and 36
Subject Global Impression (SGI) Scale
Tidsramme: Days 8, 15, 22, 29 and 36
Days 8, 15, 22, 29 and 36
Clinician Global Impression (CGI) Scale
Tidsramme: Days 8, 15, 22, 29 and 36
Days 8, 15, 22, 29 and 36
Hand Strength as Measured by the Grip Test and Pinch Tests
Tidsramme: Days 1, 8, 15, 22, 29, and 36
Days 1, 8, 15, 22, 29, and 36

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Acorda Therapeutics

Efterforskere

  • Studieleder: Mathews Adera, MD, Acorda Therapeutics

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. maj 2012

Primær færdiggørelse (Faktiske)

1. februar 2013

Studieafslutning (Faktiske)

1. marts 2013

Datoer for studieregistrering

Først indsendt

21. maj 2012

Først indsendt, der opfyldte QC-kriterier

23. maj 2012

Først opslået (Skøn)

25. maj 2012

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

22. januar 2016

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

18. december 2015

Sidst verificeret

1. december 2015

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • DALF-PS-1003

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner